SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivotal readout reportedly close.

At a share price of $10.29, SELLAS Life Sciences Group has seen a very large 1 year total shareholder return. The 90 day share price return of 108.72% contrasts with a 30 day share price decline of 30.28%, suggesting momentum has cooled as investors wait for the Phase 3 REGAL readout and process the recent arbitration setback.

If this kind of high risk biotech story has your attention, it can be useful to compare it with other specialised opportunities in healthcare AI by scanning 41 healthcare AI stocks.

After such a sharp swing in SELLAS Life Sciences Group, the key debate now shifts to valuation. Is the recent pullback simply clearing room for more upside, or has the stock already priced in most of the good news?

Preferred Price-to-Book Multiple of 18.8x: Is It Justified?

At $10.29 a share, SELLAS Life Sciences Group is trading on a P/B of 18.8x, which is far higher than many biotech peers and raises questions about what the market is paying for today.

The price to book ratio compares a company’s market value to its net assets on the balance sheet. For a business like SELLAS Life Sciences Group that is still loss making and reports no meaningful revenue, investors often lean on P/B because earnings based multiples are not yet useful. A high P/B can signal that investors are assigning significant value to the company’s pipeline and future potential rather than its current financials.

Here, the contrast with the broader US Biotechs industry is clear. SLS trades on a P/B of 18.8x, while the industry average sits at 2.4x and the peer average is 5.2x. That is a large premium for a company that is currently unprofitable, has reported a net loss of $29.457m, and has a value score of 0 on this framework. For anyone looking at SELLAS Life Sciences Group, the key question is whether the forecast revenue and earnings improvements are enough to justify such a gap.

Result: Price-to-book of 18.8x (OVERVALUED)

However, this story can change quickly if the Phase 3 REGAL data underwhelms or if SELLAS Life Sciences Group needs fresh capital on less favorable terms.

Next Steps

Given the mix of caution and optimism around SELLAS Life Sciences Group, it makes sense to review the full picture yourself and move quickly if needed. You can weigh both the upside case and the concerns by checking the 1 key reward and 3 important warning signs

Looking for more ideas beyond SELLAS Life Sciences Group?

If you are serious about finding the next opportunity, do not stop with SELLAS Life Sciences Group. Use the Simply Wall St screener to spot other stocks before the crowd.

• Target potential value opportunities by scanning companies that appear cheap against fundamentals through the 56 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses highlighted in the 89 resilient stocks with low risk scores which may suit investors who want to limit downside.
• Hunt for overlooked prospects using the screener containing 20 high quality undiscovered gems that may not yet be widely followed by the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.